By Ethan Covey
A novel combination of bictegravir (BIC; Biktarvy, Gilead) and lenacapavir (LEN; Sunlenca, Gilead) appears highly effective in maintaining viral suppression among virologically suppressed people with HIV switched from a complex antiretroviral therapy (ART), according to findings presented at AIDS 2024 (abstract OAB2602).
“Once-daily, single-tablet regimens [STRs] are the global standard for HIV treatment,” said Sorana Segal-Maurer, MD, the director of The Dr. James J.